1 At present, FDA has approved elranatamab for patients with multiple myeloma who are relapsed/refractory after at least 4 ...

Tony Newberne is a high-risk myeloma survivor. He is also a CPT, dietary manager, and patient advocate for several nonprofits ...

Although it was receiving revenue from eight products, royalties from Johnson & Johnson (JNJ) subsidiary Janssen’s ...

Anita D'Souza, MD, discusses an abstract looking at the combination of teclistamab-cqyv, daratumumab, and pomalidomide in 2 ...

Study of frail older adult patients with myeloma showed reduced disease progression and death with a regimen reducing dexamethasone exposure.

Multiple Myeloma, a cancer of the plasma cells in the bone marrow, is the third most common blood cancer in Europe. Despite recent advanced in treatment that has increased survival, it is still an ...

Opna Bio AG has presented promising data regarding their EP300/CBP inhibitor OPN-6602 for the treatment of multiple myeloma (MM). The inhibition of EP300/CBP causes cell cycle arrest and apoptosis in ...

Shared decision-making (SDM) in multiple myeloma (MM) allows for the concerns and priorities of patients, care partners, and physicians to be carefully weighed before a therapeutic course of action is ...

Updated results from the DREAMM-7 trial support the use of belantamab mafodotin plus bortezomib and dexamethasone “as a potential new standard of care,” according to Vania Hungria, MD, PhD.

When hiring job candidates to work on cell and gene therapies, companies look for more than just technical skills. Talent ...

A high-fiber diet may lessen complications after a stem cell transplant, while a ketogenic diet could help CAR-T therapy work ...

A significant overall survival (OS) benefit with belantamab mafodotin (belantamab; Blenrep) in a phase III trial of relapsed ...